EDN1 and hypertensive disorder: Although there is significant evidence supporting the involvement of ET-1 in the pathophysiology of hypertension [13], clinical trials have not yet convincingly demonstrated the efficacy of ET receptor antagonists as a treatment for systemic or resistant hypertension.